Mesoblast Limited
MESO
$18.37
$0.724.08%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
10/21/2025
-
MarketBeat
10/20/2025
-
TipRanks Financial Blog
10/20/2025
-
Nasdaq News: Markets
10/19/2025
-
Globe Newswire
Mesoblast (MESO, $17.07) entered Downtrend as Momentum indicator drops below 0 level on Oct 17, 2025
10/18/2025
-
Tickeron - Stocks
10/17/2025
-
Tickeron - Technical Analysis
10/16/2025
-
Insider Monkey
10/14/2025
-
Insider Monkey
10/14/2025
-
Tickeron - Technical Analysis
10/14/2025
-
TipRanks Financial Blog
10/14/2025
-
TipRanks Financial Blog
10/11/2025
-
Tickeron - Stocks
10/10/2025
-
MarketBeat
10/9/2025
-
Tickeron - Stocks
10/9/2025
-
Tickeron - Stocks
10/8/2025
-
MarketBeat
10/8/2025
-
TipRanks Financial Blog
10/8/2025
-
Tickeron - Stocks
10/7/2025
-
TipRanks Financial Blog
10/7/2025
-
SeekingAlpha
10/7/2025
-
Tickeron - Technical Analysis
10/7/2025
-
GuruFocus
10/7/2025
-
GuruFocus
10/7/2025
-
TipRanks Financial Blog
10/7/2025
-
Seeking Alpha - Healthcare
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, August 28, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
61 3 9639 6036
Address
55 Collins Street
Melbourne, VIC 3000
Melbourne, VIC 3000
Country
Year Founded
Business Description
Sector
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s...
more